Firebrick Pharma Ltd News

Firebrick Pharma Ltd: Change of Director's Interest Notice - Peter Molloy

Jun 28 15:04

Firebrick Pharma Ltd: Nasodine Phase 1 Paper Published

Jun 17 06:19

Firebrick Pharma Ltd: Firebrick Launches Nasodine in Singapore

Jun 13 06:24

Firebrick Pharma Ltd: Nasodine Composition Patent Granted in South Africa

May 23 06:18

Firebrick Pharma Ltd: Notice of Change in Auditor

May 6 11:26

Firebrick Pharma Ltd: March 2024 Quarterly Activity Report & Appendix 4C

Apr 23 06:26

Firebrick Pharma Ltd: Nasodine Nasal Spray Launch in the USA

Apr 17 06:31

Firebrick Pharma Ltd: Nasodine Phase 2 COVID-19 Trial Results Published

Apr 2 06:50

Firebrick Pharma Ltd: Nasodine COVID-19 Patent Allowed in US

Mar 4 06:20

Firebrick Pharma Ltd: December 2023 Quarterly Activity Report & Appendix 4C

Jan 23 13:33

Firebrick Pharma Ltd: Release of Securities from Escrow

Jan 12 07:14

Firebrick Pharma Ltd: Firebrick Closes AAT Appeal

Dec 27, 2023 05:30

Firebrick Pharma Ltd: Nasodine COVID-19 Patent Granted in South Africa

Nov 29, 2023 05:39

Firebrick Pharma Ltd: Firebrick Investor Update

Nov 15, 2023 05:47

Firebrick Pharma Ltd: Firebrick Receives $1.81m R&D Tax Incentive

Oct 31, 2023 06:06

Firebrick Pharma Ltd: September 2023 Quarterly Activity Report & Appendix 4C

Oct 27, 2023 05:49

Firebrick Pharma Ltd: Update on Nasodine Trial and Forward Plans

Oct 3, 2023 06:11

Firebrick Pharma Ltd: Notice of AGM and Closing Date for Director Nominations

Sep 18, 2023 09:45

Firebrick Pharma Ltd: Phase 3 Common Cold Trial Results

Sep 13, 2023 07:42

Firebrick Pharma Ltd: Trading Halt

Sep 11, 2023 07:37